Zogenix grabs rare disease drug in $35M buyout; Angion withdraws IPO; Ultragenyx nabs orphan drug designation;

@FierceBiotech: Sarepta plunges as CEO moves goal line on Duchenne MD drug downfield. Report | Follow @FierceBiotech

@JohnCFierce: Les Echos and Bloomberg both say Viehbacher future in doubt at Sanofi ... among the chief irritants: Viehbacher's move to Boston. | Follow @JohnCFierce

@DamianFierce: Viehbacher's letter to the $SNY board is a wincing read. "Ask Len Schleifer about me!" | Follow @DamianFierce

@EmilyMFierce: Managers of discredited STAP stem cell study refund salary. More from Science | Follow @EmilyMFierce

> San Diego-based Zogenix has acquired the U.K.'s Brabant Pharma for $35 million in cash and stock. The buyout gives Zogenix the experimental drug Brabafen, which is designed to treat Dravet syndrome, a rare form of epilepsy. A small study involving 15 patients concluded that 93% of them were either seizure-free or demonstrated a much lower rate of seizures during treatment. Release

> Angion Biomedica became the latest biotech victim to cite unfavorable "market conditions" in withdrawing its attempt at an IPO. Story

> Rare disease specialist Ultragenyx Pharmaceutical reports that the FDA has granted its orphan drug designation for triheptanoin (UX007) for the treatment of glucose transporter type-1 deficiency syndrome. Release

Medical Device News

@FierceMedDev: ICYMI Friday: New microscope offers 3D cellular images that are fast, detailed and low toxicity. Article | Follow @FierceMedDev

@VarunSaxena2: Edwards profit up 23%, but increased TAVR competition looming. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI Friday: $JNJ scores victory in first metal-on-metal hip implant case to go to trial. Article | Follow @EmilyWFierce

> St. Jude Medical snags FDA approval for next-generation ablation catheter. More

> Attorney: FDA final guidance on product recalls not helpful. Story

> Boston Children's Hospital debuts 'Baby MEG' brain imaging system. Article

Pharma News

@FiercePharma: EMA favors AstraZeneca's ovarian cancer drug Lynparza that FDA committee dissed. ICYMI Friday | Follow @FiercePharma

@EricPFierce: #Novorossiya gets subpoenaed for information about a manufacturing plant in #DenmarkHill. More | Follow @EricPFierce

@CarlyHFierce: Fed up with Allergan obstinance, Valeant CEO says he'd hike bid past $200 a share. News | Follow @CarlyHFierce

> Novartis unloads last piece of vaccines puzzle to CSL for $275M. Story

> Merck bogged down by slumping sales, but cuts deliver on profits. Article

> Is Viehbacher's job in danger? Some Sanofi directors are agitating for change, says Les Echos. Report

CRO News

> SRI's CRO cuts the ribbon on a new early-phase outpost. Item

> MPI buys out a CRO neighbor to bolster early-stage R&D. More

> CROs line up to advise Big Pharma's R&D think tank. Story

> WuXi teams up with Foundation Medicine to bring cancer profiling to China. Article

> Icon posts another revenue jump and dials up its expectations. Report

Biotech IT News

> Billionaire doc teams with Oxford Uni to build 'NASA of biomedicine.' More

> NIH-funded registry of patient-entered genetic data goes live. News

> 23andMe steps up R&D with new hire, poster push. Report

> Human Longevity backer creates $100M fund for 'crazy' ideas. Story

> Microsoft makes cloud-computing available to Ebola researchers. Article

Animal Health News

> USDA awards $4.5M to vets working in underserved areas. Article

> VCA beats Q3 estimates on same-store hospital sales growth. Report

> Are flea-fighting pills gaining ground on OTC topicals? Item

> K-State, Lawrence Livermore team on Dx tools to detect infectious diseases. Story

> Report: Pet owners jump on the probiotics bandwagon. More

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

City of Hope and Canadian biotech Biovaxys Technology reported positive animal data for their COVID vaccines that could offer alternatives to mRNA.

4D is adding a trio of executives to spearhead its work in heart, eye and lung diseases as it pushes programs into and through the clinic.

Janssen has sent off its mutation-specific non-small cell lung cancer drug amivantamab to the FDA.